The rising incidence of multiple myeloma (MM) in Malaysia, combined with limited access to newer therapies, highlights the need for locally adapted clinical guidance. This consensus aimed at establishing expert recommendations for the management of MM within Malaysia's resource-variable healthcare system. A modified Delphi process was conducted with 11 haematologists. To inform evidence-based recommendations, a targeted literature review was performed from January 2012 to June 2025. These recommendations were then evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria. A total of 58 consensus statements were developed across various areas, including diagnosis, staging, treatment of newly diagnosed and relapsed/refractory disease, renal impairment, infection prevention, high-risk smouldering myeloma, and supportive care. Agreement was assessed using a three-point Likert scale, with all statements achieving ≥ 80% consensus. Consensus recommendations highlighted that triplet induction remains the minimum standard for transplant-eligible patients in Malaysia. Quadruplet regimens deliver deeper responses and improved survival but are limited by regulatory and cost barriers across Asian health systems. In transplant-ineligible patients, treatment should be individualised based on age, frailty, cytogenetic risk, comorbidities, and financial considerations. Novel cellular and immune-based therapies, including CAR-T cells and bispecific antibodies, offer meaningful benefit in heavily pretreated disease, though availability remains restricted. Infection prophylaxis, immunoglobulin support, vaccination, and proactive management of myeloma-related bone disease are essential components of comprehensive care. Continued efforts to improve access to advanced diagnostics, novel therapies, and clinical trial participation will be critical to further enhance outcomes. This consensus provides a standardised, evidence-based framework to optimise MM care and improve patient outcomes nationally.

Keywords: Malaysia; Multiple myeloma treatment; Multiple myeloma diagnosis; Infection prevention; Multiple myeloma; Medical protocols; Consensus (Social sciences); Scale analysis (Psychology); Risk assessment; Immunization; Health services accessibility; Cancer relapse; Income; Disease management; Frail elderly; Immunoglobulins; Age distribution; Treatment effectiveness; Conceptual structures; Delphi method; Tumor classification; Kidney diseases; Individualized medicine; Evidence-based medicine; Induction chemotherapy; Medical care costs; Genetics; Comorbidity

1. National Comprehensive Cancer Network. (2025). Multiple myeloma (Version 1.2025). NCCN. Retrieved February 1, 2025, from https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
3. Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., et al. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778–779. https://doi.org/10.1002/ijc.33588
4. International Agency for Research on Cancer. (2024). Global Cancer Observatory: Cancer today. IARC. Retrieved November 20, 2025, from https://gco.iarc.who.int/today
5. Diao, X., Ben, T., Cheng, S., Niu, S., Gao, L., & Xia, N. (2025). Global, regional, and national multiple myeloma burden from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health, 25(1), Article 1054. https://doi.org/10.1186/s12889-025-22240-2
6. Chng, W. J., Nagarajan, C., Huang, S. Y., Malhotra, P., Hwang, Y. Y., Blunk, V., et al. (2024). A systematic review on the epidemiology and treatment options of multiple myeloma in Asia. Heliyon, 10(21), Article e39698. https://doi.org/10.1016/j.heliyon.2024.e39698
7. de Mel, S., Chen, Y., Gopalakrishnan, S. K., Ooi, M., Teo, C., Tan, D., et al. (2017). The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Medical Journal, 58(2), 55–71. https://doi.org/10.11622/smedj.2016150
8. Cheong, C. S., Tengku, K. A. T. A. H., Anuar, N. A., Bee, P. C., Chin, E. F. M., Khairullah, S., et al. (2024). Treatment pattern and outcome of newly diagnosed multiple myeloma patients in a resource-limited setting. Asian Pacific Journal of Cancer Prevention, 25(2), 595–601. https://doi.org/10.31557/APJCP.2024.25.2.595
9. Universiti Malaya. (2025). Universal in name, equitable in quality: Re-framing Malaysia's public healthcare expenditure from spending to investment. Retrieved December 21, 2025, from https://swrc.um.edu.my/Reports%20and%20Books/Working%20Paper/WP3.3SEPT2025.pdf
10. Rajkumar, S. V. (2024). Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 99(9), 1802–1824. https://doi.org/10.1002/ajh.27422
11. Shang, Z. (2023). Use of Delphi in health sciences research: A narrative review. Medicine, 102(7), Article e32829. https://doi.org/10.1097/MD.0000000000032829
12. Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., et al. (2004). Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches. The GRADE Working Group. BMC Health Services Research, 4(1), Article 38. https://doi.org/10.1186/1472-6963-4-38
13. OCEBM Levels of Evidence Working Group. (2011). The Oxford 2011 levels of evidence. Retrieved January 10, 2025, from https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
14. Tan, D., Lee, J. H., Chen, W., Shimizu, K., Hou, J., Suzuki, K., et al. (2018). Recent advances in the management of multiple myeloma: Clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th International Myeloma Workshop. Leukemia & Lymphoma, 59(10), 2305–2317. https://doi.org/10.1080/10428194.2018.1427858
15. Dalkey, N., & Helmer, O. (1951). The use of experts for the estimation of bombing requirements: A project Delphi experiment. RAND Corporation.
16. International Myeloma Working Group. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. British Journal of Haematology, 121(5), 749–757. https://doi.org/10.1046/j.1365-2141.2003.04355.x
17. Nightingale, B., Decker, M., Ryan, R., Kaczmarczyk, K., Jandir, P., Waykole, T., et al. (2024). Multiple myeloma: A review of the literature and a case report highlighting the immunocompromised state of myeloma patients. World Journal of Oncology, 15(3), 348–354. https://doi.org/10.14740/wjon1780
18. Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., et al. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, 15(12), e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
19. Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., et al. (2007). Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New England Journal of Medicine, 356(25), 2582–2590. https://doi.org/10.1056/NEJMoa070389
20. Lakshman, A., Paul, S., Rajkumar, S. V., Ketterling, R. P., Greipp, P. T., Dispenzieri, A., et al. (2018). Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 32(8), 1811–1815. https://doi.org/10.1038/s41375-018-0030-3
21. Neben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., et al. (2013). Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. Journal of Clinical Oncology, 31(34), 4325–4332. https://doi.org/10.1200/JCO.2012.48.4923
22. Rajkumar, S. V., Gupta, V., Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., et al. (2013). Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia, 27(8), 1738–1744. https://doi.org/10.1038/leu.2013.86
23. Cho, J., Lee, D. H., Yoo, G., Kim, J., & Uh, Y. (2022). Comparison of serum and urine free light chain analysis in clinical diagnosis. Blood Research, 57(4), 284–289. https://doi.org/10.5045/br.2022.2022187
24. Oliveros Conejero, R., Pascual Usandizaga, P., & Garrido Chércoles, A. (2020). Optimization of workflow and screening panels for the detection of malignant monoclonal gammopathies. Advances in Laboratory Medicine, 1(3), Article 20200042. https://doi.org/10.1515/almed-2020-0042
25. Putchen, D. D., & Ramaprasad, S. (2024). Laboratory approaches to enhance early detection of multiple myeloma and improve patient outcomes. Journal of Diagnostics and Academic Pathology, 1(1), 33–35. https://doi.org/10.4103/jdap.jdap_10_24
26. de Mel, S., Tso, A. C., Soekojo, C. Y., Ooi, M. G., Lim, C. C., Teo, C., et al. (2025). Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma. Annals of the Academy of Medicine, Singapore, 54(9), 561–584. https://doi.org/10.47102/annals-acadmedsg.2025322
27. Dimopoulos, M., Kyle, R., Fermand, J. P., Rajkumar, S. V., San Miguel, J., Chanan-Khan, A., et al. (2011). Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. Blood, 117(18), 4701–4705. https://doi.org/10.1182/blood-2010-10-299529
28. Jimmy, J., Jha, V., Ajeesh, G., Aryalakshmi, B., Sidharthan, N., & Unni, M. (2024). Clinical utility of 7-probe FISH panel in multiple myeloma in a resource-constrained setting: A retrospective and prospective observational study. Cancer Research, Statistics, and Treatment, 7(2), 171–177. https://doi.org/10.4103/crst.crst_210_23
29. Bong, I. P. N., & Esa, E. (2023). Molecular genetic aberrations in the pathogenesis of multiple myeloma. Asian Biomedicine, 17(4), 152–162. https://doi.org/10.2478/abm-2023-0056
30. Hillengass, J., Moulopoulos, L. A., Delorme, S., Koutoulidis, V., Mosebach, J., Hielscher, T., et al. (2017). Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group. Blood Cancer Journal, 7(8), Article e599. https://doi.org/10.1038/bcj.2017.78
31. Talarico, M., Barbato, S., Cattabriga, A., Sacchetti, I., Manzato, E., Restuccia, R., et al. (2025). Diagnostic innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma. Journal of Bone Oncology, 51, Article 100669. https://doi.org/10.1016/j.jbo.2025.100669
32. Brieghel, C., Slordahl, T. S., Andersen, M. N., Szabo, A. G., Niemann, C. U., & Thorsteinsdottir, S. (2025). A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 15(1), Article 59. https://doi.org/10.1038/s41408-025-01268-y
33. Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., et al. (2015). Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group. Journal of Clinical Oncology, 33(26), 2863–2869. https://doi.org/10.1200/JCO.2015.61.2267
34. Greipp, P. R., San Miguel, J., Durie, B. G., Crowley, J. J., Barlogie, B., Bladé, J., et al. (2005). International staging system for multiple myeloma. Journal of Clinical Oncology, 23(15), 3412–3420. https://doi.org/10.1200/JCO.2005.04.242
35. D'Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., et al. (2022). Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project. Journal of Clinical Oncology, 40(29), 3406–3418. https://doi.org/10.1200/JCO.21.02614
36. Abdallah, N. H., Binder, M., Rajkumar, S. V., Greipp, P. T., Kapoor, P., Dispenzieri, A., et al. (2022). A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 12(1), Article 21. https://doi.org/10.1038/s41408-022-00611-x
37. Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., et al. (2013). Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings, 88(4), 360–376. https://doi.org/10.1016/j.mayocp.2013.01.019
38. Cao, Y., Gong, Y., Zhou, X., & Sun, C. (2023). Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients. Hematology, 28(1), Article 2208914. https://doi.org/10.1080/16078454.2023.2208914
39. Mohyuddin, G. R., Rubinstein, S. M., Kumar, S. K., Rajkumar, S. V., Fonseca, R., Abdallah, N., et al. (2024). Performance of newer staging systems for myeloma in a contemporary, large cohort of patients in the United States. Blood Cancer Journal, 14(1), Article 95. https://doi.org/10.1038/s41408-024-01076-w
40. Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., et al. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, 17(8), e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
41. Kitundu, J. H. (2025). Redefining cure in multiple myeloma: Are we chasing a moving target? Health Science Reports, 8(12), Article e71581. https://doi.org/10.1002/hsr2.71581
42. Rajkumar, S. V. (2008). Treatment of myeloma: Cure vs control. Mayo Clinic Proceedings, 83(10), 1142–1145. https://doi.org/10.4065/83.10.1142
43. Tschautscher, M. A., Jevremovic, D., Buadi, F. K., Lacy, M. Q., Gertz, M. A., Dispenzieri, A., et al. (2020). Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 10(10), Article 95. https://doi.org/10.1038/s41408-020-00363-6
44. Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., et al. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120(9), 1801–1809. https://doi.org/10.1182/blood-2012-04-422683
45. Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., et al. (2017). Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 31(10), 2094–2103. https://doi.org/10.1038/leu.2017.29
46. Kim, H. Y., Yoo, I. Y., Lim, D. J., Kim, H. J., Kim, S. H., Yoon, S. E., et al. (2022). Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Annals of Laboratory Medicine, 42(5), 558–565. https://doi.org/10.3343/alm.2022.42.5.558
47. Paiva, B., Puig, N., García-Sanz, R., & San Miguel, J. F. (2015). Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clinical Cancer Research, 21(9), 2001–2008. https://doi.org/10.1158/1078-0432.CCR-14-2841
48. Paiva, B., van Dongen, J. J., & Orfao, A. (2015). New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood, 125(20), 3059–3068. https://doi.org/10.1182/blood-2014-11-568907
49. Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., Chretien, M. L., et al. (2018). Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 132(23), 2456–2464. https://doi.org/10.1182/blood-2018-06-858613
50. Moreau, P., & Rajkumar, S. V. (2016). Multiple myeloma—Translation of trial results into reality. Lancet, 388(10040), 111–113. https://doi.org/10.1016/S0140-6736(16)30954-0
51. Derman, B. A., Jasielec, J. K., & Jakubowiak, A. J. (2020). Clinician attitudes and practices toward measurable residual disease in multiple myeloma. British Journal of Haematology, 190(3), 470–472. https://doi.org/10.1111/bjh.16805
52. Perrot, A. (2025). Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma. La Presse Médicale, 54(1), Article 104262. https://doi.org/10.1016/j.lpm.2024.104262
53. Fu, W., Li, W., Hu, J., An, G., Wang, Y., Fu, C., et al. (2023). Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: Updated analysis of LEPUS. Clinical Lymphoma, Myeloma and Leukemia, 23(1), e51–e58. https://doi.org/10.1016/j.clml.2022.10.007
54. Kim, J. S., Song, Y., Jen, W. Y., Chim, C. S., Lee, J. J., Yoon, S. S., et al. (2025). Randomized phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: An Asian Myeloma Network study (AMN003). Blood Cancer Journal, 15(1), Article 155. https://doi.org/10.1038/s41408-025-01356-z
55. Teoh, G., Chen, Y., Kim, K., Srivastava, A., Pai, V. R., Yoon, S. S., et al. (2012). Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 12(2), 118–126. https://doi.org/10.1016/j.clml.2011.11.002
56. Zheng, W., Wei, G., Ye, X., He, J., Li, L., Wu, W., et al. (2009). Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leukemia Research, 33(12), 1615–1618. https://doi.org/10.1016/j.leukres.2009.04.006
57. Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., et al. (2017). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet, 389(10068), 519–527. https://doi.org/10.1016/S0140-6736(16)31594-X
58. Wang, Y. C., Lin, C. H., Su, Y. C., & Teng, C. J. (2025). Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A systemic review and meta-analysis. Hematology, 30(1), Article 2462249. https://doi.org/10.1080/16078454.2025.2462249
59. Mina, R., Musto, P., Rota-Scalabrini, D., Paris, L., Gamberi, B., Palmas, A., et al. (2023). Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncology, 24(1), 64–76. https://doi.org/10.1016/S1470-2045(22)00693-3
60. Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giralt, S., Agrawal, V., et al. (2022). Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation. Transplantation and Cellular Therapy, 28(2), 83.e1–83.e9. https://doi.org/10.1016/j.jtct.2021.10.022
61. Ebraheem, M. S., Chakraborty, R., Rochwerg, B., Visram, A., Mohyuddin, G. R., Venner, C. P., et al. (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Blood Advances, 8(23), 5993–6002. https://doi.org/10.1182/bloodadvances.2024014139
62. Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., et al. (2024). Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncology, 25(8), 1003–1014. https://doi.org/10.1016/S1470-2045(24)00282-1
63. Pawlyn, C., Menzies, T., Davies, F. E., de Tute, R. M., Henderson, R., Cook, G., et al. (2022). Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - Data from the Myeloma XI Trial. Blood, 140(Suppl. 1), 1371–1372. https://doi.org/10.1182/blood-2022-165376
64. Gay, F., Jackson, G., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., et al. (2018). Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis. JAMA Oncology, 4(10), 1389–1397. https://doi.org/10.1001/jamaoncol.2018.2961
65. Barlogie, B., Anaissie, E., van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., et al. (2007). Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. British Journal of Haematology, 138(2), 176–185. https://doi.org/10.1111/j.1365-2141.2007.06639.x
66. Ahmed, A., Dima, D., Row, K., Ullah, F., Awada, H., Basali, D., et al. (2023). Outcomes of salvage VDT-PACE-like regimens in relapsed-refractory multiple myeloma: 10-year experience of a large academic institution. Blood, 142(Suppl. 1), 4724. https://doi.org/10.1182/blood-2023-182972
67. Lakshman, A., Singh, P. P., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., et al. (2018). Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 93(2), 179–186. https://doi.org/10.1002/ajh.24954
68. Kaiser, M., Pratt, G., Bygrave, C., Bowles, K., Stern, S., Jenner, M., et al. (2024). Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society good practice paper. British Journal of Haematology, 205(3), 833–839. https://doi.org/10.1111/bjh.19623
69. Kaiser, M. F., Hall, A., Walker, K., Sherborne, A., De Tute, R. M., Newnham, N., et al. (2023). Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. Journal of Clinical Oncology, 41(23), 3945–3955. https://doi.org/10.1200/JCO.22.02567
70. Moore, S., Miller, H., Parrish, C., Seymour, F., Miller, L., Chandler, T., et al. (2025). Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group. British Journal of Haematology, 207(5), 1789–1801. https://doi.org/10.1111/bjh.70041
71. Fonseca, R., Rossi, A., Medhekar, R., Voelker, J., Homan, T., Wilcock, J., et al. (2024). Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: Double-blinded Delphi panel. Future Oncology, 20(23), 1645–1656. https://doi.org/10.1080/14796694.2024.2342228
72. Facon, T., Moreau, P., Weisel, K., Goldschmidt, H., Usmani, S. Z., Chari, A., et al. (2025). Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia, 39(4), 942–950. https://doi.org/10.1038/s41375-024-02505-2
73. Facon, T., San-Miguel, J., Dimopoulos, M. A., Mateos, M. V., Cavo, M., van Beekhuizen, S., et al. (2022). Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: A systematic literature review and network meta-analysis. Advances in Therapy, 39(5), 1976–1992. https://doi.org/10.1007/s12325-022-02083-8
74. Morgan, G. J., Gregory, W. M., Davies, F. E., Bell, S. E., Szubert, A. J., Brown, J. M., et al. (2012). The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 119(1), 7–15. https://doi.org/10.1182/blood-2011-06-357038
75. Dimopoulos, M. A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., et al. (2010). Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 28(33), 4976–4984. https://doi.org/10.1200/JCO.2010.30.8791
76. Soleymanian, T., Soleimani, A., Musavi, A., Mojtahedi, K., & Hamid, G. (2016). Outcome of patients with multiple myeloma and renal failure on novel regimens. Saudi Journal of Kidney Diseases and Transplantation, 27(2), 335–340. https://doi.org/10.4103/1319-2442.178557
77. Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H. S., Ullah, F., et al. (2022). Multiple myeloma therapy: Emerging trends and challenges. Cancers, 14(17), Article 4082. https://doi.org/10.3390/cancers14174082
78. Fu, C., Zhai, Y., Yan, L., Jin, S., Shang, J., Shi, X., et al. (2025). Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy. Chinese Medical Journal, 138(19), 2399–2410. https://doi.org/10.1097/CM9.0000000000003655
79. Gengenbach, L., Graziani, G., Reinhardt, H., Rösner, A., Braun, M., Möller, M. D., et al. (2021). Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers, 13(17), Article 4320. https://doi.org/10.3390/cancers13174320
80. Vera-Cruz, S., Jornet Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., et al. (2024). Cellular therapies for multiple myeloma: Engineering hope. Cancers, 16(22), Article 3867. https://doi.org/10.3390/cancers16223867
81. San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., et al. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379
82. Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., et al. (2026). Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. New England Journal of Medicine, 394(8), 739–752. https://doi.org/10.1056/NEJMoa2514663
83. Martino, E. A., Carida, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., et al. (2025). A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients. ESMO Open, 10(8), Article 105514. https://doi.org/10.1016/j.esmoop.2025.105514
84. Seehaus, C. M., Remaggi, G., Filho, J. S., Ochoa, P., Bigni, R., de Magalhães, R. J. P., et al. (2026). Burden of treatment, treatment sequencing and healthcare resource utilization in multiple myeloma in Latin America: A targeted literature review. Oncology and Therapy, 14, 113–154. https://doi.org/10.1007/s40487-025-00400-z
85. Tan, C. J., Kacerek, D., Kampirapawong, N., Godara, A., & Chaiyakunapruk, N. (2025). Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review. Cancer Medicine, 14(5), Article e70585. https://doi.org/10.1002/cam4.70585
86. Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., et al. (2019). Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. New England Journal of Medicine, 381(8), 727–738. https://doi.org/10.1056/NEJMoa1903455
87. Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., et al. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 33(9), 2266–2275. https://doi.org/10.1038/s41375-019-0435-7
88. Mateos, M. V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., et al. (2022). LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 36(5), 1371–1376. https://doi.org/10.1038/s41375-022-01531-2
89. Stalker, M. E., & Mark, T. M. (2022). Clinical management of triple-class refractory multiple myeloma: A review of current strategies and emerging therapies. Current Oncology, 29(7), 4464–4477. https://doi.org/10.3390/curroncol29070355
90. Tariq, S. M., Khalid, M. F., Noor, J., Khamees, I., Warraich, S. Z., Faisal, M. S., et al. (2025). Outcomes with non-BCMA CAR T cell therapy for multiple myeloma: A systematic review and meta-analysis. Journal of Clinical Oncology, 43(16_Suppl.), Article e19541. https://doi.org/10.1200/JCO.2025.43.16_suppl.e19541
91. Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., et al. (2022). Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group. Lancet Haematology, 9(2), e143–e161. https://doi.org/10.1016/S2352-3026(21)00283-0
92. Lonial, S., Bowser, A. D., Chari, A., Costello, C., Krishnan, A., & Usmani, S. Z. (2023). Expert consensus on the incorporation of anti-CD38 monoclonal antibody therapy into the management of newly diagnosed multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 23(11), 815–824. https://doi.org/10.1016/j.clml.2023.07.001
93. Lim, K. J. C., & Quach, H. (2023). The role of intravenous immunoglobulin (IVIG) in reducing infection risk in multiple myeloma (MM) patients receiving immune-based therapies: A single center experience. Blood, 142(Suppl. 1), 6671. https://doi.org/10.1182/blood-2023-173893
94. Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., et al. (2020). Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. Journal of Clinical Oncology, 38(11), 1126–1137. https://doi.org/10.1200/JCO.19.01740
95. Ntanasis-Stathopoulos, I., Filippatos, C., Malandrakis, P., Kastritis, E., Terpos, E., Dimopoulos, M. A., et al. (2025). Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. Blood Cancer Journal, 15(1), Article 104. https://doi.org/10.1038/s41408-025-01312-x
96. Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., et al. (2018). Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 8(6), Article 59. https://doi.org/10.1038/s41408-018-0077-4
97. Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., et al. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3), Article e61. https://doi.org/10.1002/hem3.61
98. Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., et al. (2025). Daratumumab or active monitoring for high-risk smoldering multiple myeloma. New England Journal of Medicine, 392(18), 1777–1788. https://doi.org/10.1056/NEJMoa2409029
99. Mohan Lal, B., & Al Hadidi, S. (2025). Daratumumab for high-risk smoldering multiple myeloma - Are we there yet? European Journal of Cancer, 220, Article 115391. https://doi.org/10.1016/j.ejca.2025.115391
100. Mohyuddin, G. R., Chakraborty, R., Cliff, E. R. S., & Derman, B. A. (2023). Clinician preferences on treatment of smoldering myeloma: A cross-sectional survey. EClinicalMedicine, 65, Article 102272. https://doi.org/10.1016/j.eclinm.2023.102272
101. Bernstein, Z. S., Kim, E. B., & Raje, N. (2022). Bone disease in multiple myeloma: Biologic and clinical implications. Cells, 11(15), Article 2308. https://doi.org/10.3390/cells11152308
102. Wang, Y., Xu, Q., Li, Y., Su, Y., Wang, L., Wang, X., et al. (2025). Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease. Cancer Pathogenesis and Therapy, 3(4), 280–292. https://doi.org/10.1016/j.cpt.2024.12.002
103. Terpos, E., Zamagni, E., Lentzsch, S., Drake, M. T., García-Sanz, R., Abildgaard, N., et al. (2021). Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, 22(3), e119–e130. https://doi.org/10.1016/S1470-2045(20)30559-3
104. Huang, S. Y., Yoon, S. S., Shimizu, K., Chng, W. J., Chang, C. S., Wong, R. S., et al. (2020). Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, randomized controlled phase 3 study—Asian subgroup analysis. Advances in Therapy, 37(7), 3404–3416. https://doi.org/10.1007/s12325-020-01395-x
105. Dadana, S., Gundepalli, S., & Kondapalli, A. (2023). Severe refractory hypocalcemia caused by denosumab. Cureus, 15(6), Article e39866. https://doi.org/10.7759/cureus.39866
106. LeBlanc, R., Bergstrom, D. J., Cote, J., Kotb, R., Louzada, M. L., & Sutherland, H. J. (2022). Management of myeloma manifestations and complications: The cornerstone of supportive care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) consensus guideline consortium. Clinical Lymphoma, Myeloma and Leukemia, 22(1), e41–e56. https://doi.org/10.1016/j.clml.2021.07.028